As so far, several ‘classical’ PTP are attractive therapeutic targets, including PTP1B for obesity and type II diabetes; SHP2 for cancer and Lyp for rheumatoid arthritis [6]. Here, PTPN1 is linked to type 2 diabetes mellitus.